Yannick Plétan

864 total citations
27 papers, 561 citations indexed

About

Yannick Plétan is a scholar working on Economics and Econometrics, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Yannick Plétan has authored 27 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Economics and Econometrics, 5 papers in Pharmacology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Yannick Plétan's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Pharmaceutical Economics and Policy (5 papers) and Treatment of Major Depression (5 papers). Yannick Plétan is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Pharmaceutical Economics and Policy (5 papers) and Treatment of Major Depression (5 papers). Yannick Plétan collaborates with scholars based in France, Denmark and Germany. Yannick Plétan's co-authors include A. Tournoux, J.D. Guelfi, J. J. López-Ibor, J. F. Prost, Siegfried Kasper, Martine Jandrot‐Perrus, Matthias Macháček, Mauri J. Mattila, Tapio Kuitunen and Kristell Lebozec and has published in prestigious journals such as Circulation, PLoS ONE and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Yannick Plétan

25 papers receiving 537 citations

Peers

Yannick Plétan

PHARM

PMH

CCM

CMN

HEMAT

Vincent Shu United States

Jiří Masopust Czechia

Jean Louis Montastruc France

Michel Mallaret France

R. Dirksen Netherlands

Nila Bhana New Zealand

F Rossi Italy

M. M�ller Germany

RM Poole United States

Vincent Shu United States

Yannick Plétan

91 ×0.4

PHARM

433 ×2.7

PMH

63 ×0.6

CCM

184 ×2.3

CMN

92 ×1.3

HEMAT

Citations per year, relative to Yannick Plétan Yannick Plétan (= 1×) peers Vincent Shu

Countries citing papers authored by Yannick Plétan

Since Specialization

Citations

This map shows the geographic impact of Yannick Plétan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yannick Plétan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yannick Plétan more than expected).

Fields of papers citing papers by Yannick Plétan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yannick Plétan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yannick Plétan. The network helps show where Yannick Plétan may publish in the future.

Co-authorship network of co-authors of Yannick Plétan

This figure shows the co-authorship network connecting the top 25 collaborators of Yannick Plétan. A scholar is included among the top collaborators of Yannick Plétan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yannick Plétan. Yannick Plétan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Plétan, Yannick, et al.. (2024). Relative Bioavailability Study of Midazolam Intramuscularly Administered with the Needle-Free Auto-Injector ZENEO® in Healthy Adults. Neurology and Therapy. 13(4). 1155–1172. 3 indexed citations

Pottecher, Julien, François Raffi, Martine Jandrot‐Perrus, et al.. (2024). Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial. PLoS ONE. 19(6). e0302897–e0302897. 3 indexed citations

Jandrot‐Perrus, Martine, Julien Pottecher, Esther Toledano, et al.. (2023). PB0364 Glycoprotein VI-Targeted Antiplatelet Therapy with Glenzocimab is Safe in Patients Exposed to Current Antithrombotic and Fibrinolytic Drugs. Research and Practice in Thrombosis and Haemostasis. 7. 101499–101499. 1 indexed citations

Pottecher, Julien, et al.. (2022). A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS).. 2878–2878. 1 indexed citations

Mazighi, Mikaël, Yannick Plétan, Bertrand Lapergue, et al.. (2019). Abstract 14738: Actimis Trial: Safety and Efficacy Evaluation of ACT017, a Novel Antiplatelet Agent on Top of Acute Ischemic Stroke Standard of Care. Circulation. 1 indexed citations

Lebozec, Kristell, Peter Dogterom, Philippe Billiald, et al.. (2019). Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arteriosclerosis Thrombosis and Vascular Biology. 39(5). 956–964. 87 indexed citations

Lapeyre‐Mestre, Maryse, Claudine Sapède, Nicholas Moore, et al.. (2013). Pharmacoepidemiology Studies: what Levels of Evidence and how can They be Reached?. Therapies. 68(4). 247–252. 13 indexed citations

Béhier, Jéhan‐Michel, et al.. (2013). État des lieux 2012 de l’attractivité de la France pour la recherche clinique internationale : 6e enquête du Leem. Therapies. 68(1). 1–18. 5 indexed citations

Béhier, Jéhan‐Michel, et al.. (2011). Place de la France dans la recherche clinique internationale : enquête 2010 du Leem France et recherche clinique internationale. Therapies. 66(1). 1–15. 5 indexed citations

10.

Béhier, Jéhan‐Michel, et al.. (2008). La France, un pays attractif pour la recherche clinique internationale : enquête 2008 du Leem. Therapies. 63(5). 345–357. 5 indexed citations

11.

Plétan, Yannick, et al.. (2007). L’industriel du médicament face aux effets indésirables des médicaments. Annales Pharmaceutiques Françaises. 65(5). 308–314. 1 indexed citations

12.

Trinquet, Françoise, et al.. (2006). La France est un pays attractif pour la recherche clinique internationale : enquête 2006 du Leem. Therapies. 61(5). 407–418. 7 indexed citations

13.

Guelfi, J.D., M. Ansseau, Emmanuelle Corruble, et al.. (1998). A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. International Clinical Psychopharmacology. 13(3). 121–128. 43 indexed citations

14.

Tignol, Jean-Pierre, et al.. (1998). Double‐blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major dipressive episode. Acta Psychiatrica Scandinavica. 97(2). 157–165. 37 indexed citations

15.

Plétan, Yannick, et al.. (1997). An International Medico-Economic Survey of 2007 Children with Recurrent Nasopharyngitis and Acute Otitis Media. Drugs. 54(Supplement 1). 5–12. 5 indexed citations

16.

Lecrubier, Y., et al.. (1996). Clinical efficacy of milnacipran. International Clinical Psychopharmacology. 11. 29–34. 44 indexed citations

17.

Kasper, Siegfried, et al.. (1996). Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression. International Clinical Psychopharmacology. 11. 35–40. 70 indexed citations

18.

López-Ibor, J. J., J.D. Guelfi, Yannick Plétan, A. Tournoux, & J. F. Prost. (1996). Milnacipran and selective serotonin reuptake inhibitors in major depression. International Clinical Psychopharmacology. 11. 41–46. 94 indexed citations

19.

Mattila, Mauri J., Tapio Kuitunen, & Yannick Plétan. (1992). Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. European Journal of Clinical Pharmacology. 43(2). 179–184. 31 indexed citations

20.

Stupfel, M, et al.. (1983). Environmental parameters in the experimental evaluation of a respiratory aggression.. PubMed. 2(1). 67–73. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact